Finerenone Reduces Albuminuria via Hemodynamic Mechanisms Rather Than Improving Arterial Stiffness: Insights from the FIVE-STAR Trial
Posted inCardiology Nephrology news

Finerenone Reduces Albuminuria via Hemodynamic Mechanisms Rather Than Improving Arterial Stiffness: Insights from the FIVE-STAR Trial

The FIVE-STAR trial demonstrates that while finerenone significantly reduces albuminuria in patients with T2D and CKD, it does not improve arterial stiffness (CAVI). These findings suggest that its cardiorenal benefits are primarily driven by intraglomerular pressure modulation rather than systemic vascular remodeling.
Datopotamab Deruxtecan Redefines Progression-Free Survival in HR+/HER2- Breast Cancer Despite Neutral Overall Survival Results
Posted innews Oncology

Datopotamab Deruxtecan Redefines Progression-Free Survival in HR+/HER2- Breast Cancer Despite Neutral Overall Survival Results

The final TROPION-Breast01 analysis confirms datopotamab deruxtecan's superior progression-free survival over chemotherapy in HR+/HER2- breast cancer. While overall survival did not reach significance, likely due to subsequent ADC crossover, the drug maintains a favorable safety profile and clinical utility.